Clinical trials: Controlled Hypertension
- Condition Controlled Hypertension
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Endothelial Dysfunction, Hyperhomocysteinemia
Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function
The effect of a combination product (Verum ) with L-arginine, Pycnogenol, vitamin K2, R-(+)-alpha-lipoic acid and vitamins B6, B12 and folic acid is investigated in a double blind placebo-controlled cross-over study.
- Conditions
- Endothelial Dysfunction, Hyperhomocysteinemia, Hypertension Grade I, Subgroup "Borderline" (WHO)
- Trial name
- NCT02392767
- Testing
- Verum
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dr. Loges & Co. GmbH
Healthy Adult, Hypertension
A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with…
- Trial name
- NCT07609875
- Testing
- HS-10522
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Healthy, Diabetes
Safety for 24 Weeks Intake of Korean Red Ginseng in Adults
Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce body fat, URTI prevention, cardiovascular risk, renal…
- Conditions
- Healthy, Diabetes, Hypertension, Hyperlipidemia
- Trial name
- NCT02428998
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Korea Ginseng Corporation
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
Multiple-Ascending Dose in Japanese Patients Bridging Study
This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy Japanese and Caucasian subjects.
- Trial name
- NCT05065359
- Testing
- Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Altavant Sciences GmbH
Pre-hypertension
A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults
This study will investigate the effect of a nitric oxide supplementation product, Neo40 Daily®, on blood pressure in pre-hypertensive and mildly hypertensive adults.
- Trial name
- 15NBHN (NCT02679248)
- Testing
- Neo40 Daily®
- Where
- 2 sites in Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Open Angle Glaucoma, Ocular Hypertension
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT05456724
- Testing
- TO-O-1001
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Theratocular Biotek Co.
Hypertension
The PK/PD Study of SHR0532 Tablets in Healthy Subjects
In the last four decades, several classes of diuretics have been the first line option for the therapy of widespread hypertension. However, all the classes of diuretics cause alteration of potassium homeostasis.
- Trial name
- NCT03645278
- Testing
- SHR0532
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Overweight and Obesity
Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.
- Trial name
- NCT03986775
- Testing
- isomaltulose, sucrose
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Subjects With Mild Hypertension
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
- Trial name
- NCT07117474
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Cardiovascular Disease+Pulmonary Disease, Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
This is a single centre, double-blind, randomised, placebo-controlled, parallel staggered group study of BIA 5-1058 in 11 different cohorts of 15 healthy subjects.
- Trial name
- NCT03708146
- Testing
- BIA 5-1058
- Where
- United Kingdom
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hyperlipidemias, Hypertension
The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure
In this randomized, placebo-controlled, double-blind parallel study in human participants with elevated LDL-C and elevated BP described here, the clinical benefits of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng…
- Trial name
- NCT04069715
- Testing
- Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- LongStar HealthPro, Inc. DBA Farlong Pharmaceutical
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Pulmonary Arterial Hypertension
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06137742
- Testing
- PF-07868489
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Hypertension
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
This is a first-in-human, single-blind, placebo-controlled, single-centre study designed to assess the safety and tolerability of PDNO in healthy male and female subjects.
- Trial name
- NCT04891354
- Testing
- PDNO
- Where
- Sweden
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Attgeno AB
Adverse Drug Event, Side Effects of Drugs
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
- Trial name
- NCT03112083
- Testing
- Nutritional counseling A, Nutritional counselling B
- Where
- Finland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Olympic Seafood AS
Hypertension
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.
- Trial name
- NCT07254481
- Testing
- VB19055
- Where
- 2 sites in China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.